CARsgen's satri-cel included in China's Innovative Drug List
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
CARsgen Therapeutics Holdings Limited announced that its drug, satricabtagene autoleucel (satri-cel), has been included in the Commercial Health Insurance Innovative Drug List (CHIIDL) for 2026. The list, issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, covers advanced gastric/gastroesophageal junction adenocarcinoma patients who have failed at least two prior lines of therapy. The inclusion takes effect on January 1, 2027.
From prnewswire.com
Why it matters
The CHIIDL provides a payment basis for China's multi-tiered healthcare security system, covering highly innovative drugs that exceed basic insurance mandates. Satri-cel is noted as the first CAR T-cell therapy product for solid tumors to be added to the list since its establishment.
From prnewswire.com
Who's involved
- Zonghai LiHolds executive roles at the company
- companyAnnounced the drug inclusion in Suzhou
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ChinaSpeculative
The inclusion in the CHIIDL might expand market access and revenue potential for the healthcare sector in China.
Keep exploring
The entities involved
-
Suzhou
prefecture-level city in Jiangsu, China, former capital of the kingdom of Wu
Nothing else this week.
-
Zonghai Li
researcher
Nothing else this week.